(Q35048594)

6 August 2017

0 references

1 reference

title

Leflunomide for treating rheumatoid arthritis (English)

1 reference

6 August 2017

1 reference

6

1 reference

6 August 2017

M Osiri

1

1 reference

6 August 2017

B Shea

2

1 reference

6 August 2017

V Robinson

3

1 reference

6 August 2017

M Suarez-Almazor

4

1 reference

6 August 2017

V Strand

5

1 reference

6 August 2017

G Wells

7

1 reference

6 August 2017

publication date

1 January 2003

1 reference

Cochrane Database of Systematic Reviews

6 August 2017

published in

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

CD002047

1 reference

Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002047

When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002047

A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002047

A randomized, controlled, single-blind trial of leflunomide in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002047

Weekly dose of leflunomide for the treatment of refractory rheumatoid arthritis: an open pilot comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002047

Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002047

Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002047

Efficacy and safety of leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoid arthritis: multinational double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002047

Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002047

Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002047

Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002047

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002047

Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002047

The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002047

The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002047

Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002047

The effects of leflunomide on clinical parameters and serum levels of IL-6, IL-10, MMP-1 and MMP-3 in patients with resistant rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002047

The role of HLA-DRB1 shared epitope alleles in predicting short-term response to leflunomide in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002047

Long term evaluation of radiographic disease progression in a subset of patients with rheumatoid arthritis treated with leflunomide beyond 2 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002047

Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002047

Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002047

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002047

The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002047

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002047

Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002047

Developing optimal search strategies for detecting clinically sound studies in MEDLINE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002047

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002047

Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002047

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002047

New and future drug therapies for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002047

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002047

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002047

Interpreting Results and Drawing Conclusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002047

10.1002/14651858.CD002047

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference